Published in Rheumatol Int on July 26, 2007
Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging (2010) 1.14
Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des (2013) 1.00
Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int (2010) 0.85
Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis (2017) 0.82
Gout in Older Adults: The Atherosclerosis Risk in Communities Study. J Gerontol A Biol Sci Med Sci (2015) 0.78
Serum apoprotein A1 levels are inversely associated with disease activity in gout: From a southern Chinese Han population. Medicine (Baltimore) (2017) 0.75
Clinical characteristics of early- and late-onset gout: A cross-sectional observational study from a Chinese gout clinic. Medicine (Baltimore) (2016) 0.75
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum (1998) 12.36
Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med (1999) 6.72
Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med (2004) 6.53
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA (2000) 6.10
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.59
Alcohol intake and risk of incident gout in men: a prospective study. Lancet (2004) 4.12
Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med (1967) 3.65
Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis (2005) 3.53
MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest (2006) 3.21
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol (2004) 3.17
Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med (1984) 3.05
Gout and the risk of acute myocardial infarction. Arthritis Rheum (2006) 2.96
Epidemiology of gout: is the incidence rising? J Rheumatol (2002) 2.80
Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med (2005) 2.80
Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother (1993) 2.69
Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum (2005) 2.25
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol (2006) 1.79
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum (2005) 1.70
Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis (2000) 1.52
A literature review of the epidemiology and treatment of acute gout. Clin Ther (2003) 1.50
Gouty arthritis. A primer on late-onset gout. Geriatrics (2005) 1.45
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther (2006) 1.45
Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis (2006) 1.39
Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med (1975) 1.34
Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med (1991) 1.31
Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis (2002) 1.25
Effect of weight-loss on plasma and urinary levels of uric acid. Lancet (1972) 1.25
Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med (1992) 1.21
Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol (1997) 1.20
Crystal deposition disease in the elderly. Clin Rheum Dis (1986) 1.19
Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. Rheumatology (Oxford) (2006) 1.18
Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis (2005) 1.08
Diuretic-induced gout in elderly women. Br J Rheumatol (1985) 1.07
Female gout: clinical and laboratory features. J Rheumatol (2005) 1.07
Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest (1993) 1.06
Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes (1986) 1.05
Recent developments in diet and gout. Curr Opin Rheumatol (2006) 1.02
Colchicine myotoxicity: case reports and literature review. Pharmacotherapy (2004) 1.00
Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol (1999) 0.98
Gout in Heberden's nodes. Arthritis Rheum (1983) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum (1990) 0.96
Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens (1999) 0.94
New insights into gout epidemiology. Curr Opin Rheumatol (2006) 0.90
Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol (2007) 0.90
Diuretic induced gout: a multifactorial condition. Ann Rheum Dis (1992) 0.90
Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest (1979) 0.89
Gout in the elderly, a separate entity? Ann Rheum Dis (1987) 0.87
Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch Nutrition Surveillance System). J Clin Epidemiol (1990) 0.85
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant (2001) 0.84
Nodal osteoarthritis and gout: a report of four new cases. Skeletal Radiol (1996) 0.82
Rheumatoid factors in the serum of gouty patients. Arthritis Rheum (1977) 0.81
Fingertip tophi without gouty arthritis. Dermatology (1993) 0.79
Newer therapeutic approaches: gout. Rheum Dis Clin North Am (2006) 0.79
Finger pad tophi. Cutis (1999) 0.78
Advances in the management of gout and hyperuricaemia. Scand J Rheumatol (2006) 0.76
Podagra is more than gout. Bull Rheum Dis (1984) 0.75
Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum (2009) 1.71
Paget's disease of bone: a review. Rheumatol Int (2008) 1.50
Thrombocytosis in systemic lupus erythematosus: a possible clue to autosplenectomy? J Rheumatol (2007) 1.45
Increased risk of myocardial infarction with dabigatran: fact or fiction? J Cardiovasc Med (Hagerstown) (2014) 1.42
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine (2012) 1.41
Clinical predictors in chronic articular adult-onset Still's disease: comment on the article by Ichida et al. Arthritis Care Res (Hoboken) (2014) 1.39
Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) (2010) 1.34
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Adult-onset Still's disease. Rheumatol Int (2009) 1.27
Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem (2003) 1.24
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford) (2014) 1.14
"SAPHO syndrome and infections". Autoimmun Rev (2008) 1.08
Autosplenectomy and antiphospholipid antibodies in systemic lupus erythematosus: A pathogenetic relationship? Semin Arthritis Rheum (2003) 1.06
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum (2009) 1.06
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther (2011) 1.04
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) (2011) 1.04
HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics (2006) 1.02
Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum (2009) 0.98
Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum (2007) 0.98
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol (2008) 0.98
Networking properties of cyclodextrin-based cross-linked polymers probed by inelastic light-scattering experiments. J Phys Chem B (2012) 0.96
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol (2006) 0.95
Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford) (2010) 0.94
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev (2010) 0.92
Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res (2013) 0.92
Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. J Rheumatol (2002) 0.91
Effect of cross-linking properties on the vibrational dynamics of cyclodextrins-based polymers: an experimental-numerical study. J Phys Chem B (2012) 0.91
Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech (2011) 0.90
Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation. Rheumatol Int (2008) 0.90
Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm (2009) 0.90
Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther (2013) 0.90
HLA-G may predict the disease course in patients with early rheumatoid arthritis. Hum Immunol (2012) 0.89
Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) (2009) 0.88
Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol (2013) 0.88
Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using Doppler measures of myocardial strain. J Am Soc Echocardiogr (2008) 0.87
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLoS One (2013) 0.87
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem (2009) 0.87
Nanosponge formulations as oxygen delivery systems. Int J Pharm (2010) 0.86
The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum (2011) 0.86
Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J (2012) 0.86
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci (2012) 0.86
CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica (2008) 0.86
Detection of Chlamydophila pneumoniae in patients with arthritis: significance and diagnostic value. Rheumatol Int (2010) 0.86
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis (2013) 0.86
Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions. Int J Cardiol (2012) 0.85
Catalytic properties of catechol 1,2-dioxygenase from Acinetobacter radioresistens S13 immobilized on nanosponges. Dalton Trans (2009) 0.85
Digital clubbing or digital "pseudoclubbing" in systemic sclerosis. J Clin Rheumatol (2006) 0.85
The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol (2010) 0.85
Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. Clin Exp Rheumatol (2013) 0.84
Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a beta-cyclodextrin/poly(amidoamine) copolymer. J Control Release (2007) 0.84
Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int (2006) 0.84
Minor salivary gland biopsy and Sjögren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers. Clin Exp Rheumatol (2012) 0.83
The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev (2010) 0.83
Inside new materials: an experimental numerical approach for the structural elucidation of nanoporous cross-linked polymers. J Phys Chem B (2012) 0.83
High-definition polymeric membranes: construction of 3D lithographed channel arrays through control of natural building blocks dynamics. ACS Appl Mater Interfaces (2010) 0.83
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv (2010) 0.83
Treating rheumatoid arthritis to target: an Italian rheumatologists' survey on the acceptance of the treat-to-target recommendations. Clin Exp Rheumatol (2014) 0.83
Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. Medicine (Baltimore) (2015) 0.83
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol (2013) 0.82
Enhanced antiviral activity of Acyclovir loaded into beta-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles. J Control Release (2009) 0.82
Nanosponges encapsulating dexamethasone for ocular delivery: formulation design, physicochemical characterization, safety and corneal permeability assessment. J Biomed Nanotechnol (2013) 0.82
Haematological anticancer drugs in Europe: any added value at the time of approval? Eur J Clin Pharmacol (2007) 0.82
Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. Br J Clin Pharmacol (2013) 0.82
Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol (2011) 0.82
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. J Med Chem (2014) 0.81
Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. Int J Pharm (2012) 0.81
Increased sensitivity to extracellular ATP of fibroblasts from patients affected by systemic sclerosis. Ann Rheum Dis (2007) 0.81
Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatol Int (2008) 0.80
Polymorphonuclear neutrophils and instability of the atherosclerotic plaque: a causative role? Inflamm Res (2013) 0.80
The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.80
Whipple disease: unusual presentation of a protean and sometimes confusing disease. Semin Arthritis Rheum (2008) 0.80
Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature. Rheumatol Int (2011) 0.80
Cyclin D3 critically regulates the balance between self-renewal and differentiation in skeletal muscle stem cells. Stem Cells (2013) 0.80
Glucocorticoid receptors and bone. Curr Pharm Des (2010) 0.79
The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? Rheumatology (Oxford) (2010) 0.79
Cyclodextrin nanosponge-sensitized enantiodifferentiating photoisomerization of cyclooctene and 1,3-cyclooctadiene. Beilstein J Org Chem (2012) 0.79